The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback